

Date: 10th November, 2023

To, Listing Department, BSE Limited, Floor 25, PJ Tower Dalal Street, Mumbai – 400 001 Script Code: 540359

Sub.: Outcome of the meeting of the Board of Directors of the Company

Dear Sirs,

In continuation of our Corporate announcement dated 3rd November, 2023 we hereby inform you that the Board of Directors of the Company has, at its meeting held today, inter—alia, considered and approved the Unaudited Financial Results for quarter and half year ended 30th September, 2023. The same has also been reviewed by the Audit Committee in its meeting held today. A copy of the Statement of Unaudited Financial Results for the quarter and half year ended 30th September, 2023.

Further we are submitting the Limited Review report on Unaudited Financial Results for quarter and half year ended 30^{th} September, 2023 issued by our Statutory Auditors i.e. M/ s. B A Shah S R Mehta & Co.

The meeting was concluded at 02:30 pm.

Kindly take this on your records.

Thanking you,

Yours faithfully,

For, Parmax Pharma Limited

YASH
JAYESHBHAI
VORA
Digitally signed by YASH
JAYESHBHAI VORA
Date: 2023.11.10
14:38:59 +05'30'

Yash J. Vora Company Secretary

Encl: As above



	Statement of Standalone Una	duited Results	Tor the quarter o				// 5
							(In Rs. Thousands)
	Particulars –	Quarter Ended			Half Year Ended		Year Ended
r. o.		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Revenue from operations	40680.96	14001.43	21338.18	54682.38	36891.73	154243.
- 1	Other income	93.34	136.95	77.21	230.30	161.21	397.
- 1	Total Income (I+II)	40774.30	14138.38	21415.39	54912.68	37052.94	154640.
	Expenses						
- 11	(a) Cost of materials consumed	13824.44	2827.89	4923.70	16652.33	17725.61	55136
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	13525.27	1460.76	3405.12	14986.03	-4590.51	-210
		0400 54	7240.02	E121 22	15739.46	10602.38	28017
	(d) Employee benefits expense	8489.54	7249.92	5121.32 1170.99	3029.70	2085.04	100 (87)(-15
	(e) Finance Costs	1812.56	1217.14	4666.53	8510.44	9280.61	100000000000000000000000000000000000000
	(f) Depreciation and amortisation expense	4322.62	4187.81		974 - 800 (Sept.) (Sept.)		1075
	(g) Other expenses	12484.09	8983.79	9153.53	21467.88	22156.50	liceration.
	Total expenses (IV)	54458.52	25927.32	28441.19	80385.84	57259.64	154179
	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-13684.23	-11788.94	-7025.81	-25473.17	-20206.70	
	Exceptional Items	0.00	0.00	0.00	0.00		
	Profit/ (Loss) before tax (V-VI)	-13684.23	-11788.94	-7025.81	-25473.17	-20206.70	46
1	Tax expense:		0.000				
	(1) Current tax	0.00		0.00	0.00		
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	34
	Net Profit / (Loss) for the period from	-13684.23	-11788.94	-7025.81	-25473.17	-20206.70	-104
	continuing operations (VII-VIII)	1,224,041,045		W 0000000			
	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	2
	Tax expense of discontined operations	0.00	0.00	0.00	0.00	0.00	0
	Profit/(loss) from Discontined operations (after tax) (X-XI)	0.00		0.00	0.00	0.00	0
1	Profit (Loss) for the period (IX+XII)	-13684.23	-11788.94	-7025.81	-25473.17	-20206.70	-104
V	Other Comprehensive Income A. (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B. (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss	0.00		0.00	0.00	0.00	0
ΧV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	-13684.23	-11788.94	-7025.81	-25473.17	-20206.7	0 -104
νI	Paid-up equity share capital (Face Value Rs 10)	37413.00	37413.00	37413.00	37413.00	37413.0	0 3741
ΚVII	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each): (a) Basic (In Rs)	-3.66	5 -3.15	-1.88	-6.81	L -5.4	0
	(b) Diluted	-3.00	-3.15	-1.00	-0.0.	1 -3.4	

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311 Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail: info@parmaxpharma.com CIN: L24231GJ1994PLC023504 ADALLA LA

Mfg. of: Bulk Drugs, Drug Intermediates & Speciality Chemicals



Notes:

- 1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 10.11.2023
- 2. The Stautory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and half year ended 30th September, 2023
- 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
- 4. Statement of Unaudited Financial Results of the company for the Quarter and half ended 30th September, 2023 in the prescribed format under Schedule III of Companies Act, 2013
- 5. The figures for the previous period have been regrouped wherever necessary.
- * The Company has decided to gradually write off its all Preliminary and Pre-oprative expenses which are forming the part of Balance Sheet accordingly Company has writen off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

FOR, PARMAX PHARMA LIMITED

Dr. Umang Gosalia Managing Director

Place: Rajkot

Date: 10.11.2023





	STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2023		(In Rs. Thousands)
		As at 30.09.2023	As at 31.03.2023
Sr. No.	Particulars	(Unaudited)	(Audited)
		(Onaudited)	Paddica
l.	Assets		
1	Non-current assets	91124.46	95004.81
	(a) Property, Plant and Equipment	0.00	
	(b) Capital work-in-progress	0.00	
	(c) Investment Property		50000000
	(d) Goodwill	0.00	100.4176.210
	(e) Other Intangible assets	0.00	2-04 7-032
	(f) Intangible assets under development	0.00	
	(g) Biological Assets other than bearer plants	0.00	
	(h) Financial Assets	0.00	
	(i) Investments	6.00	TO SECURE
	(ii) Trade receivables	0.00	
	(iii) Loans	2637.34	1865.84
	(i) Deferred tax assets (net)	0.00	0.00
	(j) Other non-current assets	1980.70	3961.40
	Total Non-Current Assets	95748.50	100838.04
2	Current assets		
2	(a) Inventories	23882.50	43061.06
	(b) Financial Assets	0.0	50 TO 100
	V-19	0.0	
	(i) Investments	22217.3	
	(ii) Trade receivables	1389.6	
	(iii) Cash and cash equivalents	0.0	
	(iv) Bank balances other than(iii) above	10991.0	VO.
	(v) Loans		Warrage a
	(vi) Others (to be specified)	0.0	
	(c) Current Tax Assets (Net)	0.0	
2	(d) Other current assets	172.0	
	Tatal Current Assets		24
	Total Asset:	s 154401012.	1 176126.3
11.	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share capital	44511.5	44511.5
	(b) Other Equity	-12655.0	14047.1
	Total Equity	31856.4	7 58558.6
2	LIABILITIES		
i	Non-current liabilities	0.0	00
ļ.	(a) Financial Liabilities	0.0	
	(i) Borrowings	54871.6	
		0.0	
-	(ii) Trade payables (iii) Trade payables (iii) Trade payables	0.0	
	(iii)Other financial liabilities (other than those specified in item (b), to be specified	0.0	-
	(b) Provisions	1410.6	
	(c) Deferred tax liabilities (Net)		
	(d) Other non-current liabilities	0.0	
	Total of Non-Current Liabilitie	es 88138.7	74 104760.1
ii.	Current liabilities		
	(a) Financial Liabilities	0.0	
	(i) Borrowings	0.0	
	(ii) Trade payables	48746.	No. 10. 10. 10. 10. 10. 10. 10. 10. 10. 10
National Control	(iii) Other financial liabilities (other than those specified in item (c)	0.0	
	(b) Other current liabilities	8607.	27 15037.0
	(c) Provisions	8908.	11 9687.
	(d) Current Tax Liabilities (Net)	0.	0.0
	Total of Current Liabilitie	es 66262.	27 71366.
	Total Equity and Liabilities	154401.	

FOR, PARMAX PHARMA LIMITED

HADAMTALA

Place: Rajkot Date: 10.11.2023 PARMAX PHARMA LIMITED

Dr. Umang Gosalia
Managing Director

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail: info@parmaxpharma.com CIN: L24231GJ1994PLC023504



	CASH FLOW STATEMENT FOR THE HAL	F YEAR END	DED 30TH SEPTEMBE	R, 2023	
				(A	mt. Rs. Thousands)
	PARTICULARS		Half Year Period Ended on 30/09/2023	Half Year Period Ended on 30/09/2022	Period Ended on 31/03/2023
			Unaudited	Unaudited	Audited
<u>(A)</u>	CASH FLOW FROM OPERATING ACTIVITIES				
	Net Profit After Extraordinary Item but Before Taxation:		-26702.15	-20206.69	461.23
	Adjustments for:			1	
	Depreciation		8510.44	9280.61	18785.72
	Provision for Current Tax		0.00	0.00	1850.00
	Current tax expenses relating to prior year				14.83
	Provision for Deferred Tax Assets		0.00	0.00	-362.92
	Operating profit before Working Capital changes		-18191.71	-10926.08	17382.12
	Adjustments for changes in Working Capital:				
	(Increase) / Decrease in Inventories		19178.56	759.53	-14536.06
	(Increase) / Decrease in Trade & Other Receivables		-15989.85	3711.83	541.53
	(Increase) / Decrease in Short term Loans and Advances		10768.81	4497.64	-2171.78
	Increase / (Decrease) in Current Liabilities		-5103.85	-13351.89	-2126.42
	Increase / (Decrease) in Tax Provisions		0.00	0.00	350.78
	(Increase) / Decrease in Non Current Assets		1980.70	1980.70	3961.40
	(Increase) / Decrease in Long term Loans & Advances		-771.51	-2125.62	-70.62
	Cash generated from Operations		10062.86	-4527.81	-14051.16
	Net Cash from Operating activities	(A)	-8128.85	-15453.89	3330.96
<u>(B)</u>	CASH FLOW FROM INVESTING ACTIVITIES				
	Purchase of Fixed Assets		-4630.09	-5158.44	-9363.99
	Net Cash from / (Used in) Investing activities	(B)	-4630.09	-5158.44	-9363.99
(C)	CASH FLOW FROM FINANCING ACTIVITIES				
	Increase / (Decrease) in other Long Term Borrowings		10080.69	10558.93	-441.58
	(Increase)/ Decrease in Non Current Investment		0.00		
	Net Cash (Used in) Financing activities	(C)	10080.69	10558.93	-441.5
	Net Increase in Cash & Cash Equivalents (A + B + C)		-2678.2	-10053.40	-6474.6
	Cash & Cash Equivalents at the beginning of the year		4067.9	10542.5	10542.5
	Cash & Cash Equivalents at the end of the year		1389.6	6 489.1	2 4067.9

FOR, PARMAX PHARMA LIMITED

Place: Rajkot Date: 10.11.2023

PARMAX PHARMA LIMITED

Dr. Umang Gosalia Managing Director

Regd. Off. & Factory: Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail: info@parmaxpharma.com CIN: L24231GJ1994PLC023504

BASHAHSRMEHTA& Go.

Chartered Accountants

Partner

Malay B Shah

B.Com. F.C.A.

M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of PARMAX PHARMA LTD ("the Company") for the quarter and half year ended 30th Sept 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on 10th November 2023. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Head Office:

209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:
302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD – 380 009
(GUJARAT)

<u>Electronic Address:</u> (O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or

mbshah 31@hotmail.com

BASHAHSRMEHTA& Co.

Chartered Accountants

Partner

Malay B Shah

B.Com. F.C.A.

M. No. 159526

Partner

Zarna M Shah

M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Rajkot

Date: 10.11.2023

RAJKOT COUNTRY COUNTRY

For B. A. SHAH S R MEHTA & Co.

Chartered Accountants

FRN NO: 128796W

MALAY B SHAH

Partner

M. No. 159526

UDIN: 23159526BGYPIS9295

209-Sapphire Complex, IInd Floor 21/25-B New Jagnath Plot, Dr.Yagnik Road RAJKOT- 360 001 (GUJARAT) Branch Office:
302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD – 380 009
(GUJARAT)

Electronic Address: (0) 0281-2468261

(M) 09427564149 (E) bassrmco.office@gmail.com

Or

mbshah 31@hotmail.com